Search

Copyright of Chinese Journal of Oncology Prevention & Treatment is the property of Editorial Department of Chinese Journal of Oncology Prevention & Treatment and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Practical Medicine / Shiyong Yixue Zazhi is the property of Journal of Practical Medicine Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To observe the expression changes of inhibitor of DNA binding-1 (Id-1 ) and matrix metallo-proteinase-9 (MMP-9) in the human colorectal carcinoma tissues and to discuss the clinical significance. Methods The expression of Id-1 and MMP-9 in 50 specimens of colorectal carcinoma tissues (observation group) and 50 specimens of normal colorectal tissues (control group) was detected by immunohistochemistry, RT-PCR and Western blotting. The cor-relations between their positive expression and the clinicopathological features were analyzed. Results The positive rates of Id-1 in the observation group and the control group were 72% and 24%, the positive rates of MMP-9 were 78% and 22%, respectively, and there were significant differences between these two groups (all P<0.05). The positive expression of Id-1 and MMP-9 was related with the depth of tumor invasion, TNM stage, lymph node metastasis, vessel invasion and liver metastasis (all P<0.05). The relative expression of Id-1 mRNA in the observation group and the control group was 0.96 ± 0. 03 and 0.20 ± 0.04, the relative expression of MMP-9 mRNA was 0.88 ± 0.04 and 0.21 ± 0.03, respectively, and there were significant differences (all P<0. 05). The relative expression of Id-1 protein was 0.82 ± 0.04 and 0.31 ± 0.02, the relative expression of MMP-9 in the observation group and the control group was 0.86 ± 0.05 and 0.29 ± 0.03, respectively, and there were significant differences between these two groups (all P<0.05). Conclusion The expression of Id-1 and MMP-9 was increased in the human colorectal carcinoma tissues, and the expression was related with tumor in-vasion, TNM stage, lymph node metastasis, liver metastasis and vessel invasion. [ABSTRACT FROM AUTHOR]

观察结直肠腺癌组织中长链非编码 RNA linc00511 的表达情况，并探讨其临床意义。方法　选 取 50 例结直肠腺癌患者，术后留取癌组织及癌旁组织；采用实时定量PCR 法检测linc00511，比较结直肠腺癌不同 临床病理参数及预后患者 linc00511 表达的差异。结果　结直肠腺癌组织中 linc00511 表达量为3． 20 ±1． 29，高于 癌旁组织中的1． 21 ±0． 92(P <0． 01)。淋巴结转移和远处转移的结直肠腺癌组织中 linc00511 高表达者高于无淋 巴转移、无远处转移者(P 均<0． 05)，而不同性别、年龄、肿瘤直径、组织分化程度、TNM 分期间差异无统计学意义。 linc00511 高表达和低表达者5 年生存率分别为40% (10 /25)、72% (18 /25)，linc00511 高表达者5 年生存率低于低 表达者(P <0． 05)。结论　结直肠腺癌组织中 linc00511 表达增加；其高表达可能是促进结直肠癌发生转移的重要原因之一，并有助于判断患者预. [ABSTRACT FROM AUTHOR]

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的探讨奥沙利铂+替吉奥联合多西他赛（DOS方案）新辅助化疗对老年进展期胃卜.部癌的治疗效果 及安全性。方法选取老年进展期胃上部癌患者75例，随机分为DOS组、SOX组、对照组，每组25例。DOS组行 DOS方案新辅助化疗，SOX组行SOX方案(奥沙利钼+替吉奥)新辅助化疗，直至可行根治性手术结束化疗。化疗结 束3周评佔化疗近期有效率及毒副反应情况。DOS组、SOX组新辅助化疗结束4周行胃癌根治术，对照组确诊2周内 行胃癌根治术。比较三组R0切除率、淋巴结清扫率、淋巴结转移个数及术后并发症情况。术后随访20个月，比较三 组无疾病进展时间(PFS)。结果DOS组、SOX组均顺利完成新辅助化疗，每例化疗2 ~6个周期,化疗结束3周， DOS组近期有效率为68.0%、疾病控制率为92.0%，S0X组分别为60.0%、80.0%，两组比较P均>0.05,两组毒副反 应主要为骨髓抑制、消化道反应、肝功能异常等，均可耐受。DOS组R0切除率为92.0%，S0X组为80.0%，对照组为 64.0%，组间两两比较均<0.05。DOS组淋巴结清扫率为88.0%，SOX组为80.0%，对照组为60.0%，DOS组、SOX 组均高于对照组(P均<0. 05)。DOS组淋巴结转移数目为（3.5 ±1.7)个，SOX组为（4.0 ±1.5)个，对照组为（7.1± 2.6)个，DOS组、SOX组均低于对照组(P均<0.05)。但DOS组和SOX组淋巴结清扫率、淋巴结转移数0比较P均 >0.05。三组术后并发症发生率比较P >0.05。术后随访20个月，DOS组中位PFS为19(17.928 ~20.012)个月，SOX 组为18( 16.754 ~ 19.216)个月，对照组为14( 12.762 ~ 16.471)个月，DOS组、SOX组中位PFS明显高于对照组（P均 <0.05)，但DOS组、SOX组中位PFS比较P >0.05。结论DOS方案新辅助化疗对老年进展期胃上部癌近期疗效较 好，患者耐受性较好，安全性较高，同时还能提高R0切除率、降低术后淋巴结转移率，提高患者近期生存率。 [ABSTRACT FROM AUTHOR]

Objective To detect the expression of Id-1 and matrix metalloproteinase-2 (MMP-2) in human colorectal adenocarcinoma tissues, and explore their relationships with clinicopathological characteristics and prognosis. Methods The expression levels of Id-1 and MMP-2 in 50 specimens of normal colorectal tissues, 30 specimens of colorectal adenoma tissues and 50 colorectal adenocarcinoma tissues were detected by immunohistoehemistry. and subsequently the relationships between their expression and clinical-pathological features and prognosis were analyzed. Results The positive expression rates of Id-1 in colorectal normal tissues, adenoma tissues and adenocarcinoma tissues were 24.00%, 43.33% and 72.00%, and the positive expression rates of MMP-2 in colorectal normal tissues, adenoma tissues and adenocarcinoma tissues were 24. 00% . 43. 33% and 72. 00%, all P <0. 01. The expression of Id-1 and MMP-2 was correlated with the depth of serosa invasion, TNM stages, liver metastasis, lymph node metastasis and vessel invasion, all P <0.05. The expression of Id-1 was positively correlated with the expression of MMP-2 in colorectal adenocarcinoma tissues ( r =0. 429. P = 0. 000 ). The median survival time of Id-1 positive expression and negative expression were 32 months and 43 months, and the median survival time of MMP-2 positive expression and negative expression were 28 months and 45 months, all P <0. 05. Cox proportional hazards model analysis showed that the expression of Id-1 and MMP-2 was significantly correlated with the prognosis (all P <0. 05 ). Conclusion Id-1 and MMP-2 is highly expressed in colorectal adenocarcinoma tissues and its expression is related to the occurrence, metastasis and prognosis of colorectal cancer. [ABSTRACT FROM AUTHOR]